NCT07605143

Brief Summary

Fibromyalgia is considered a condition of unknown etiology, affecting approximately 2-5% of the population in developed countries, predominantly women, and is most commonly diagnosed between the ages of 40 and 50. Its main characteristic is the presence of widespread musculoskeletal pain. Although the most frequently reported symptoms include multiple tender points, fatigue, and cognitive dysfunction, this syndrome is also commonly associated with anxiety, depression, and pain catastrophizing. In Chile, fibromyalgia accounts for up to 26.7% of private rheumatology consultations, with a similar scenario observed in the city of Concepción. This highlights the need to implement innovative therapeutic strategies that allow patients to practice motor and cognitive skills in various contexts, including occupational and domestic environments. In this regard, virtual reality has emerged as a promising tool for this population, as it provides a controlled virtual environment where patients can engage in different therapeutic techniques, moving beyond conventional treatment approaches. Through this approach, interventions may include relaxation exercises, cognitive-behavioral therapy, and adapted physical activities. Such interaction may improve cognitive function, reduce symptoms of anxiety, decrease pain perception associated with the condition, and enhance overall quality of life. This study aims to evaluate the effectiveness of a physiotherapy intervention combined with immersive virtual reality on quality of life, cognitive function, and psychological symptoms in patients diagnosed with fibromyalgia. This study corresponds to a randomized controlled crossover clinical trial in which participants will be randomly assigned to one of two groups: Group A will initiate the intervention with physical exercise using immersive virtual reality, while Group B will begin with physical exercise without virtual reality support (control condition). After completing the first intervention period, a crossover will be performed, such that Group A will continue with exercise without virtual reality and Group B will receive the immersive virtual reality intervention. In this way, all participants will experience both exercise modalities, allowing for both within- and between-subject comparisons. A washout period will be included between phases to minimize potential carryover effects. Each group will consist of 21 participants recruited from the Kinesiology Center of Universidad San Sebastián. Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA), psychological variables will be evaluated using the Depression Anxiety Stress Scales (DASS-21), and quality of life will be measured using the Fibromyalgia Impact Questionnaire-Revised (FIQ-R). All outcomes will be assessed at baseline and after each intervention phase.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 15, 2025

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 16, 2026

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 26, 2026

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

May 13, 2026

Completed
9 days until next milestone

First Posted

Study publicly available on registry

May 22, 2026

Completed
Last Updated

May 22, 2026

Status Verified

May 1, 2026

Enrollment Period

2 months

First QC Date

May 13, 2026

Last Update Submit

May 19, 2026

Conditions

Keywords

adherencefibromialgiavirtual reality

Outcome Measures

Primary Outcomes (4)

  • Quality of life

    Quality of life in patients with fibromyalgia will be assessed using the Fibromyalgia Impact Questionnaire-Revised (FIQ-R), which evaluates the impact of fibromyalgia across three dimensions: difficulty in activities of daily living during the past week, overall impact of the disease during the past week, and symptom intensity during the past week. The total score ranges from 0 to 100, with higher values indicating greater symptom severity and a higher level of functional disability

    At the beginning and end of the 6-week treatment period

  • Cognitive function

    Cognitive function in both groups will be assessed using the MoCA questionnaire, a brief cognitive assessment tool that measures performance in domains such as memory, orientation, language, attention, executive function, and visuospatial abilities. The MoCA total score ranges from 0 to 30 points, with higher scores indicating better cognitive performance. A score of 26 or higher is generally considered within the normal cognitive range, although cutoff values may vary depending on age, education level, and clinical context.

    At the beginning and end of the 6-week treatment period

  • Psychoemotional variables

    Psychoemotional variables will be assessed using the DASS-21 questionnaire, which consists of 21 items designed to evaluate the presence of stress, anxiety, and/or depression. The instrument is divided into three subscales assessing depression, anxiety, and stress, with seven items assigned to each domain. Each item is rated on a 4-point Likert scale ranging from 0 ("did not apply to me at all") to 3 ("applied to me very much or most of the time"). Higher scores indicate greater severity of psychoemotional symptoms.

    At the beginning and end of the 6-week treatment period

  • Sleep quality

    Sleep quality was assessed using the Jenkins Sleep Questionnaire, a validated instrument designed to measure the frequency of sleep-related difficulties during the previous week, including problems falling asleep, nighttime awakenings, non-restorative sleep, and fatigue upon waking. The questionnaire consists of four items rated according to the frequency of symptoms experienced, with higher scores indicating poorer sleep quality and greater sleep disturbance.

    At the beginning and end of the 6-week treatment period

Secondary Outcomes (2)

  • User experience

    At the beginning and end of the 6-week treatment period

  • Adherence to the intervention program

    At the beginning and end of the 6-week treatment period

Study Arms (2)

Immersive VR → Conventional Exercise

EXPERIMENTAL

Participants receive immersive virtual reality exercise followed by conventional exercise.

Behavioral: Virtual Reality TrainingBehavioral: convencional exercise

Conventional Exercise → Immersive VR

ACTIVE COMPARATOR

Participants receive conventional exercise followed by immersive virtual reality exercise.

Behavioral: Virtual Reality TrainingBehavioral: convencional exercise

Interventions

Participants will perform a structured physiotherapy program consisting of moderate-intensity aerobic exercise, coordination training, and relaxation techniques, delivered using immersive virtual reality systems (Meta Oculus Quest). Each session will last approximately 60 minutes and will be conducted twice per week for 6 weeks. The program includes 10 minutes of aerobic exercise (cycle ergometer), followed by immersive virtual reality activities comprising 5 minutes of warm-up, 10 minutes of coordination exercises, and 5 minutes of cool-down, concluding with stretching and breathing exercises. Exercise intensity will be monitored using the modified Borg scale. The virtual reality environment is designed to promote motor and cognitive engagement within an interactive setting.

Conventional Exercise → Immersive VRImmersive VR → Conventional Exercise

Participants will perform the same structured physiotherapy program consisting of moderate-intensity aerobic exercise, coordination training, and relaxation techniques without the use of immersive virtual reality. Each session will last approximately 60 minutes and will be conducted twice per week for 6 weeks. The program includes 10 minutes of aerobic exercise (cycle ergometer), followed by therapist-guided exercises including 5 minutes of warm-up, 10 minutes of coordination exercises, and 5 minutes of cool-down, concluding with stretching and breathing exercises. Exercise intensity will be monitored using the modified Borg scale.

Conventional Exercise → Immersive VRImmersive VR → Conventional Exercise

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults aged 18 years or older
  • Medical diagnosis of fibromyalgia according to the American College of Rheumatology (ACR) criteria
  • Ability to understand and follow study instructions
  • Willingness to participate and provide written informed consent

You may not qualify if:

  • Pregnancy or breastfeeding
  • Oncological pain
  • Uncontrolled metabolic disorders
  • History of vertigo or conditions that may be exacerbated by virtual reality use
  • Any neurological or musculoskeletal condition that limits participation in exercise

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universidad San Sebastián

Concepción, Biobio, 41000, Chile

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Researcher in Musculoskeletal Rehabilitation

Study Record Dates

First Submitted

May 13, 2026

First Posted

May 22, 2026

Study Start

December 15, 2025

Primary Completion

February 16, 2026

Study Completion

February 26, 2026

Last Updated

May 22, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Individual participant data will not be shared due to ethical and confidentiality considerations. The study involves sensitive clinical information from patients with fibromyalgia, and data will be handled in accordance with institutional ethical guidelines and data protection regulations. Access to the dataset will be restricted to the research team, and all data will be stored securely in password-protected systems. No identifiable information will be disclosed to external researchers.

Locations